Literature DB >> 26837292

Atypical Endometrial Hyperplasia and Well Differentiated Endometrioid Adenocarcinoma of the Uterine Corpus.

Anne M Mills1, Teri A Longacre2.   

Abstract

The distinction between atypical endometrial hyperplasia and well differentiated adenocarcinoma of the endometrium is one of the more difficult differential diagnoses in gynecologic pathology. Different pathologists apply different histologic criteria, often with different individual thresholds for atypical endometrial hyperplasia and grade 1 adenocarcinoma. While some classifications are based on a series of molecular genetic alterations (which may or may not translate into biologically or clinically relevant risk lesions), almost all current diagnostic criteria use a series of histologic features - usually a combination of architecture and cytology - for diagnosing atypical hyperplasia and adenocarcinoma. This article presents evidence-based histologic criteria for atypical endometrial hyperplasia and low grade endometrial carcinoma (both FIGO grade 1 and 2) with emphasis on common and not so common histologic mimics. Grade 3 endometrioid carcinoma is discussed in the Oliva and Soslow article in this publication.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical endometrial hyperplasia; Endometrial hyperplasia; Endometrioid adenocarcinoma; Well differentiated endometrial adenocarcinoma

Year:  2011        PMID: 26837292     DOI: 10.1016/j.path.2010.12.007

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  2 in total

1.  Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.

Authors:  Janice B Harvey; Tanasa S Osborne; Hue-Hua L Hong; Sachin Bhusari; Tai-Vu Ton; Arun R Pandiri; Tiwanda Masinde; June Dunnick; Shyamal Peddada; Susan Elmore; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-09-08       Impact factor: 1.902

2.  Cytologic features of upper gynecologic tract adenocarcinomas exhibiting mesonephric-like differentiation.

Authors:  Brie Kezlarian; Stephanie Muller; Vitor Werneck Krauss Silva; Carlene Gonzalez; Daniel J Fix; Kay J Park; Rajmohan Murali
Journal:  Cancer Cytopathol       Date:  2019-07-18       Impact factor: 5.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.